Combination of mammalian target of rapamycin (mTOR) and histone deacetylase (HDAC) inhibitors could kill the NF-kB mutant and kirsten rat sarcoma viral oncogene (KRAS) mutant NSCLC cells by regulating the TBP-2/Trx-1 signaling pathway (22). The gene discussed is MTOR; the disease is non-small cell lung carcinoma.